Mission Therapeutics

United Kingdom - Cambridge, Cambs

• 15/03/2024
• Unknown
• $32,101,650

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.

Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.

Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas.

Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy.

Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.

The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015.

In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

Related People

Anker LundemoseFounder

United Kingdom - Greater Cambridge Area

Chief Executive Officer of MISSION Therapeutics. He has extensive experience from business and corporate development as well as R&D in several key therapeutic areas including oncology, diabetes and anti-infectives. He has a comprehensive international experience and network, and has been responsible for successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech startups, large biotech and big pharma, as well as an initial career in academia.

He was Chief Executive Officer and President of Bionor Pharma ASA from 2013 to 2015, Chief Executive Officer of Prosidion Limited in the UK from 2003 to 2005, Executive Vice President OSI Pharmaceuticals Inc. in the US and President of Prosidion Ltd from 2005 to 2009. He was Executive Vice President Corporate & Business Development, OSI Pharmaceuticals Inc., from 2009 until Astellas Pharmaceutical Inc's acquisition of OSI in 2010. He has previously held positions as Managing Director at OSI Pharmaceuticals venture arm in Zug, Switzerland, and as Business Development Director at Novo Nordisk, Denmark. Anker has MD, PhD and DMSc qualifications in medical microbiology.

LinkedIn https://www.linkedin.com/in/ankerlundemose/